GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye

by Business Wire • 2021/05/03 • 0 Comments

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that Eye, the official journal of the Royal College of Ophthalmologists (UK), has published the final results of the REALITY Leber Hereditary Optic Neuropathy (LHON) Registry study. The p

← VIDEO: Retrospective study sheds light on nature of dry eye disease flares

Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting →

Post navigation